Kidney and cardiovascular protection with SGLT2 inhibitors: lessons from cardiovascular outcome trials and CREDENCE

被引：4
|
作者：
O'Hara, D. V. [1 ,2 ]
Neuen, B. L. [1 ,2 ]
Jardine, M. J. [1 ,3 ]
机构：
[1] UNSW, George Inst Global Hlth, Sydney, NSW, Australia
[2] Royal North Shore Hosp, Sydney, NSW, Australia
[3] Concord Repatriat Gen Hosp, Sydney, NSW, Australia
来源：
JOURNAL OF NEPHROLOGY | 2020年 / 33卷 / 05期
关键词：
SGLT2; inhibitors; Type; 2; diabetes; Chronic kidney disease; Clinical outcomes; GLOMERULAR-FILTRATION-RATE; DIABETES-MELLITUS; DOUBLE-BLIND; DISEASE; EMPAGLIFLOZIN; CANAGLIFLOZIN; ALBUMINURIA; NEPHROPATHY; MECHANISMS; MORTALITY;
D O I：
10.1007/s40620-020-00809-x
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
The burden of diabetic kidney disease is rising rapidly worldwide, and new therapies are of vital importance to reduce the risk of kidney failure and major cardiovascular events. Of the newer glucose-lowering agents, sodium-glucose co-transporter 2 (SGLT2) inhibitors have shown exciting potential in preventing these adverse events. The results of several large cardiovascular outcome trials, a single dedicated kidney outcome trial and a dedicated heart failure trial, demonstrate substantial clinical benefits for several different SGLT2 inhibitors. Emerging evidence raises the possibility that these benefits may extend to those with non-diabetic chronic kidney disease. This review summarises the current evidence for SGLT2 inhibitor benefits and harms, and examines which patients are most likely to gain from these therapies.
引用
收藏
页码：977 / 983
页数：7
相关论文
共 50 条
  • [1] Kidney and cardiovascular protection with SGLT2 inhibitors: lessons from cardiovascular outcome trials and CREDENCE
    D. V. O’Hara
    B. L. Neuen
    M. J. Jardine
    [J]. Journal of Nephrology, 2020, 33 : 977 - 983
  • [2] Cardiorenal protection with SGLT2: Lessons from the cardiovascular outcome trials
    Silva-Cardoso, Jose
    Sheikh, Omar
    Nashawi, Mouhamed
    Pham, Son
    Gallegos, Kelly M.
    Dinkha, Laith R.
    Chilton, Robert J.
    [J]. JOURNAL OF DIABETES, 2020, 12 (04) : 279 - 293
  • [3] SGLT2 inhibitors: hypotheses on the mechanism of cardiovascular protection
    Bell, Robert M.
    Yellon, Derek M.
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (06): : 435 - 437
  • [4] Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function
    Vallon, Volker
    Verma, Subodh
    [J]. ANNUAL REVIEW OF PHYSIOLOGY, VOL 83, 2021, 83 : 503 - 528
  • [5] What have we learned about renal protection from the cardiovascular outcome trials and observational analyses with SGLT2 inhibitors?
    Sridhar, Vikas S.
    Rahman, Habib U.
    Cherney, David Z. I.
    [J]. DIABETES OBESITY & METABOLISM, 2020, 22 : 55 - 68
  • [6] SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study
    Abdul-Ghani, Muhammad
    Del Prato, Stefano
    Chilton, Robert
    DeFronzo, Ralph A.
    [J]. DIABETES CARE, 2016, 39 (05) : 717 - 725
  • [7] SGLT2 Inhibitors as the Backbone of Therapy for Cardiovascular and Renal Protection
    Felice Gragnano
    Fabrizia Terracciano
    Paolo Calabrò
    [J]. Journal of Cardiovascular Translational Research, 2024, 17 : 227 - 229
  • [8] Is There a Diabetes-Kidney-Heart Continuum? Perspectives From the Results of the Cardiovascular and Renal Outcome Clinical Trials With SGLT2 Inhibitors
    Bao, Liwen
    Gao, Xiufang
    Xie, Kun
    Li, Yong
    [J]. FRONTIERS IN CARDIOVASCULAR MEDICINE, 2021, 8
  • [9] SGLT2 Inhibitors as the Backbone of Therapy for Cardiovascular and Renal Protection
    Gragnano, Felice
    Terracciano, Fabrizia
    Calabro, Paolo
    [J]. JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH, 2024, 17 (01) : 227 - 229
  • [10] Cardiovascular safety of SGLT2 inhibitors
    Gumprecht, Janusz
    [J]. CLINICAL DIABETOLOGY, 2016, 5 (02): : 62 - 65
12345